entertainment -WSS

entertainment

author：explore 2025-10-01 00:49:36 - browse：696

Three boxes of Breyanzi on a dark blue background — biotech coverage from STAT — The FDA is looking into adverse events involving a number of CAR-T therapies, including Breyanzi. Illustration: STAT; Source: Business Wire

The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which uses genetically modified white blood cells to attack tumors, can in rare cases cause lymphoma, a blood cancer.

“Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action,” the agency said in a statement.

The agency noted that it is investigating reports of T cell lymphoma, including cancer cells carrying the engineered T cells, in patients who received CAR-T therapy. Experts in the field, which has produced multiple approved products to treat blood cancer, expressed surprise and puzzlement at the announcement, saying that they had not previously seen data about the risk.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： First recipient of genetically engineered pig kidney has died

WSS

CDC wastewater surveillance dashboard to track bird flu hotspots

How to protect patients from sexual assault

Brain worms: The science behind RFK Jr.'s parasitic infection

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Use wet bulb globe temperature, not heat index, to protect workers

Illumina names Agilent executive as new CEO

leisure time

entertainment

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

'Make People Better': The CRISPR babies story you probably don't know

Cancer drug shortages should be causing more outrage

Bird flu outbreak in cows is latest avian flu curveball

Dobbs anniversary: the lost opportunity of abortion as health care

Study: Adult vaccinations pay for themselves in societal benefits

Walensky prepares to leave CDC — and Congress — behind

What drug price negotiations mean for Medicare Part D

https://cbu01.alicdn.com/img/ibank/2017/067/724/4223427760_143648193.220x220xz.jpg

Making AI in medicine accessible to smaller, and rural hospitals

entertainment

The (many) problems with a new study criticizing cancer screening

Readout LOUD podcast: What to know about H5N1 bird flu

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Ethical issues complicate the benefits of medical crowdfunding

NIH nominee Bertagnolli will get October confirmation hearing

Elevance, private equity launch primary care company

focus

focus

explore

focus